Xeris Pharmaceuticals | XERS - Operating Expenses


Xeris Pharmaceuticals reported $67.65M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Celltrion KRW 724.99B 6B Sep/2025
Cspc Pharmaceutical CNY 5.4B 298.41M Sep/2025
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 40.68M 5.56M Sep/2025
Divis Laboratories Ltd INR 18.32B 1.08B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Kangmei Pharma CNY 1.39B 144.29M Sep/2025
Knight Therapeutics CAD 118.61M 11.79M Sep/2025
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Organigram Holdings CAD 108.11M 17.03M Sep/2025
Ovoca Bio EUR 5.65M 3.45M Jun/2022
Pacira USD 193.68M 27.32M Dec/2025
Perrigo USD 1.03B 75.3M Dec/2025
Pharma Mar EUR 46.87M 7.24M Dec/2025
Qiagen NV USD 418.54M 23.25M Dec/2025
Sartorius EUR 693.1M 29.4M Sep/2025
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025
Tilray USD 237.52M 17.34M Sep/2025
Zz Pientze Pharmaceu CNY 1.55B 129.66M Sep/2025